Mölnlycke Health Care acquires innovative wound therapy treatment

Mölnlycke Health Care acquires innovative wound therapy treatment

June 5 2012

Mölnlycke Health Care today announced that it has acquired a pioneering electrical stimulation technology that helps to accelerate wound healing. The product currently marketed under the name of woundEL® has been purchased from Gerromed GmbH* and is in an early phase of commercialization.

Mölnlycke Health Care’s acquisition will significantly accelerate the company’s entry into this novel treatment area for hard to heal wounds.  Non-healing wounds can be very expensive to treat, placing a burden on healthcare systems world-wide. Electrical stimulation has been shown to accelerate several aspects of the wound healing process.

Commenting on woundEL, Professor Debus, head of vascular medicine at the University Heart Center Hamburg-Eppendorf in Germany stated, “Electrostimulation with woundEL provides an effective treatment for chronic and complicated wounds and is well tolerated by the patients. I am impressed by the way the wounds appear to be triggered from the inflammatory phase to the healing phase.”

“Electrical stimulation is particularly exciting as a significant body of clinical research and evidence indicates that it provides a very cost-effective way to accelerate wound healing,” said Phil Cooper, President of the Mölnlycke Health Care Wound Care Division. “Together with the Avance® Negative Pressure Wound Therapy product line and the array of dressings utilizing Safetac® technology, this acquisition provides Mölnlycke Health Care with an extensive variety of proven wound care therapy solutions.”

The technology will be developed within Mölnlycke Health Care’s newly established Electrical Stimulation business unit (EStim). Bertrand Hughes, Business Director of EStim explained, “This innovative technology will be further developed with strategic partners and in consultation with the inventor of woundEL: Mr Lucas Garabet. The company is very excited about this technology and the benefits it will bring for patients in terms of reduced pain and avoidance of social isolation.”

The acquisition of the electrical stimulation technology follows Mölnlycke Health Care’s recent acquisition of the burn and wound care business from Brennen Medical.

Electrical stimulation in wound healing

Electrical stimulation is an area of technology with many positive healthcare applications. In recent years research in bioelectricity has shown significant links between endogenous electrical fields in the body and the wound healing process. Electrical stimulation has been shown to impact numerous healing processes including transcutaneous oxygen tension and capillary density in the tissue as well as stimulating the migration of keratinocytes, macrophages, leukocytes and fibroblasts. It is also reported to reduce oedema and wound pain.

Dr. Alexander Nill, Chairman of the board of DII Deutsche Indutrie Invest AG, main shareholder behind Gerromed GmbH comments: “We are very pleased that the wound El business, after being successfully launched in two European markets, is now being further developed by Mölnlycke Health Care with the intention of full international introduction. With the support of Mölnlycke Health Care we can ensure the future success of this advanced wound healing therapy and are convinced the technology will reach those that need it most.”

*Gerromed GmbH will continue as a separate legal entity marketing anti-decubitus mattresses.


Notes to Editor

About Mölnlycke Health Care
Mölnlycke Health Care is a world leading manufacturer of wound care and single-use surgical products and a service provider to the healthcare sector.

The Surgical Division offers safe and efficient surgical solutions through a wide range of single-use products that help minimize the risk of infections for patients and protect healthcare workers. Key brands include BARRIER®, Biogel®, and HiBi®. The Surgical Division also offers custom procedure trays, branded ProcedurePak®, that add value by creating important work-flow and cost efficiencies.

The Wound Care Division offers gentle and effective wound care solutions. Featured products include those with the unique and patented Safetac® technology that reduce unnecessary suffering during a patient’s wound healing journey. Safetac is available exclusively on Mepitel®, Mepilex® and other selected dressings. The Wound Care assortment also includes Avance®, a Negative Pressure Wound Treatment system with the unique Avance® Film with Safetac® technology and Mepiseal® soft silicone sealant. The Avance system comprise a lightweight pump and docking station giving patients greater mobility and ease of use increasing patient comfort. Dressings, compression bandages, dermatology products and retention products as well as a bioactive product are also available in the product assortment.

Mölnlycke Health Care began operating as an independent company in late 1997 and was acquired by Investor AB in January 2007. The company has about 7000 employees and manufacturing plants in Belgium, the Czech Republic, Finland, France, Malaysia, Thailand, Poland, the UK, and the US.